Medacta Group confirmed first-half revenues of EUR368 million, a 9.7% increase measured on a constant currency basis, but the result fell short of analyst expectations by approximately 1% against the EUR373 million consensus. The company disclosed the figures on Wednesday.
Regional performance was uneven. Asia-Pacific led the company with 13.1% constant currency growth, while Europe, Middle East and Africa recorded 10.0% growth. North America posted the slowest advance among major regions, expanding 6.6% on a constant currency basis. Latin America grew 16.4% on a constant currency basis.
Medacta pointed to a sales transition in its Spine business as the principal factor behind the softer revenue trend in the United States. Within the Joints category, the company observed a softening among its existing customer base.
Performance by product category varied versus consensus estimates. The Hips business rose 8.1% on a constant currency basis, close to the 8.6% consensus. Knees grew 10.8% on a constant currency basis, underperforming the 14.0% estimate. Spine increased 4.5% on a constant currency basis compared with a 7.7% estimate, while Shoulder and Sports Medicine expanded 15.9% on a constant currency basis, below the 25.0% consensus.
Despite the near-term shortfall in reported revenue, Medacta reiterated its full-year targets. The company maintained guidance for constant currency revenue growth of 10% to 14% and for an expansion in constant currency adjusted EBITDA margin of 50 basis points. The firm noted that achieving the midpoint of the revenue range would require second-half growth of roughly 14.3% on a constant currency basis.
Summary
Medacta delivered a first-half revenue increase of EUR368 million (9.7% cc), missing the EUR373 million consensus by about 1%. Regional and product-level results were mixed, with North America and several product lines trailing analyst estimates. The company maintained its full-year revenue growth and adjusted EBITDA margin guidance.
Key points
- Group revenues: EUR368 million, up 9.7% on a constant currency basis, versus consensus of EUR373 million.
- Regional divergence: Asia-Pacific +13.1% cc, EMEA +10.0% cc, North America +6.6% cc, Latin America +16.4% cc.
- Product mix: Hips +8.1% cc (vs 8.6% consensus), Knees +10.8% cc (vs 14.0%), Spine +4.5% cc (vs 7.7%), Shoulder and Sports Medicine +15.9% cc (vs 25.0%).
Risks and uncertainties
- Sales transition in the Spine business may continue to dampen revenue growth in North America - this impacts the medical devices and healthcare equipment sectors.
- Softening within the existing Joints customer base could pressure near-term sales trends in joint-replacement categories - relevant to orthopedics and surgical services.
- To hit the midpoint of full-year guidance the company needs approximately 14.3% constant currency growth in the second half - missing that pace would affect full-year revenue outcomes.
Medacta's first-half results present a mix of solid expansion in several regions and product lines alongside clear areas of underperformance versus analyst expectations. The company preserved its full-year targets, but the pace required in the second half to reach the midpoint of the revenue range is materially higher than the current first-half growth rate. Investors and market participants will likely watch execution in the Spine business in the United States and the behavior of the Joints customer base for signs that the company can accelerate revenue in the next two quarters.